To listen to the conference call dial 1-888-459-5609. International
callers can dial 1-973-321-1024. When prompted, use PIN number 83042522.
Dial in approximately ten minutes prior to the scheduled teleconference
time. A rebroadcast of the call will be available starting approximately
two hours after the conference call ends, through midnight (E.T.)
Wednesday October 4, 2017. The replay of the conference call can be
accessed by dialing 1-800-585-8367 (International callers can dial
1-404-537-3406) and, when prompted, use the same PIN number 83042522.

To listen to the live call, individuals should go to the web site at
least 15 minutes early to register, download and install any necessary
audio software. Any pop up blocker installed on your PC should be
disabled while accessing the webcast.

A press release announcing fourth quarter results will be distributed,
Wednesday, September 27, 2017 after the market closes.

Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and intellectual
property through the development of unique diagnostic platform
technologies that provide numerous advantages over previous standards. A
global company, Enzo Biochem utilizes cross-functional teams to develop
and deploy products, systems and services that meet the ever-changing
and rapidly growing needs of health care today and into the future.
Underpinning Enzo Biochem’s products and technologies is a broad and
deep intellectual property portfolio, with patent coverage across a
number of key enabling technologies.

Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management, including those related
to cash flow, gross margins, revenues, and expenses which are dependent
on a number of factors outside of the control of the Company including,
inter alia, the markets for the Company’s products and services, costs
of goods and services, other expenses, government regulations,
litigation, and general business conditions. See Risk Factors in the
Company’s Form 10-K for the fiscal year ended July 31, 2016. Investors
are cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and
uncertainties that could materially affect actual results. The Company
disclaims any obligations to update any forward-looking statement as a
result of developments occurring after the date of this press release.